Autolus Therapeutics
AUTL
67 hedge funds and large institutions have $144M invested in Autolus Therapeutics in 2022 Q2 according to their latest regulatory filings, with 13 funds opening new positions, 14 increasing their positions, 18 reducing their positions, and 11 closing their positions.
18% more first-time investments, than exits
New positions opened: 13 | Existing positions closed: 11
0% more funds holding
Funds holding: 67 → 67 (0)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
2.62% less ownership
Funds ownership: 58.53% → 55.91% (-2.6%)
22% less repeat investments, than reductions
Existing positions increased: 14 | Existing positions reduced: 18
52% less capital inflows, than outflows
Capital inflows: $7.46M | Capital outflows: $15.5M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Nantahala Capital Management
New Canaan,
Connecticut
|
+$2.42M |
| 2 |
UBS O'Connor
Chicago,
Illinois
|
+$1.17M |
| 3 |
MAI Capital Management
Independence,
Ohio
|
+$1.11M |
| 4 |
TFG Asset Management
Grand Cayman,
Cayman Islands
|
+$589K |
| 5 |
ExodusPoint Capital Management
New York
|
+$454K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$4.14M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$3.84M |
| 3 |
Deep Track Capital
Greenwich,
Connecticut
|
-$1.6M |
| 4 |
Eversept Partners
New York
|
-$1.55M |
| 5 |
Capital World Investors
Los Angeles,
California
|
-$1.33M |
AUTL Hedge Fund Activity: Q2 2022 in Review
67 of the 5,963 institutional investors tracked by Wall St. Rank reported a position in Autolus Therapeutics (AUTL) for Q2 2022, worth a combined $144M — down 37% from $229M a quarter earlier.
Buyers outnumbered sellers: 13 funds opened new AUTL positions and 11 closed out — a net gain of 2 holders — while 14 added to existing stakes and 18 trimmed.
The largest buyer was Nantahala Capital Management, adding an estimated $2.42M. The largest seller was Citadel Advisors, cutting an estimated $4.14M.
- 67 institutional investors held Autolus Therapeutics (AUTL) as of Q2 2022, unchanged from Q1 2022.
- Funds reported $144M of Autolus Therapeutics stock for Q2 2022, down 37% quarter-over-quarter.
- 13 funds opened new Autolus Therapeutics positions in Q2 2022 and 11 closed out, a net change of +2 holders.
- The largest Autolus Therapeutics buyer in Q2 2022 was Nantahala Capital Management, an estimated $2.42M added.
- The largest Autolus Therapeutics seller in Q2 2022 was Citadel Advisors, an estimated $4.14M sold.
Based on aggregated 13F filings for Q2 2022.